NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment

NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment
NICE issued its final draft guidance recommending enzalutamide (Xtandi, by Astellas Pharma) for prostate cancer (PC) patients who have already tried first-line treatments with no success, for those who have none to a few symptoms and for those who have not been recommended chemotherapy. According to a press release, the Appraisal Committee decided that enzalutamide is a cost-effective, well-tolerated treatment that delays chemotherapy, improving survival. The final draft guidance for enzalutamide is now being revised by consultees, who can appeal against it. Until NICE releases its final guidance, NHS agencies can decide locally on the funding of particular treatments. NICE is also considering preliminary recommendations that go against the support of abiraterone (Zytiga, by Janssen) as a therapy for PC that has spread after non-effective treatment, for patients who have none to mild symptoms, or for whom chemotherapy was not indicated. The Appraisal Committee recognized abiraterone’s good tolerance but did not respond positively to the evidence of long-term benefit of abiraterone, on the grounds that estimates of cost-effectiveness were substantially above what the Committee thought was reasonable. Further Notes:
  1. Enzalutamide (Xtandi, by Astellas Pharma) is recommended — in its agreed marketing terms —
    Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *